Scalper1 News
The obesity-drug business received another blow Wednesday when the FDA delayed a decision on Orexigen’s (OREX) NB32, also known as Contrave, by three months. Orexigen’s stock plunged 18% to below 6 in morning trading on the stock market. In a press release, Orexigen said that the FDA wanted more time to “reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes for NB32. The Scalper1 News
Scalper1 News